Florensocatib for bronchiectasis: safety and effectiveness study
Part of Lungs & breathing clinical trials.
This study tests whether a new tablet called florensocatib can help people with bronchiectasis (a lung disease causing chronic cough and mucus) breathe better and have fewer infections. Bronchiectasis damages the airways, and this medication may help reduce flare-ups by working on the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12–85 years old (with parental consent if under 18)
- Confirmed bronchiectasis diagnosis with CT scan showing lung damage in one or more areas
- At least 1–2 lung flare-ups treated with antibiotics in the past 12 months
- Lung function (FEV1) at least 30% of normal after using a bronchodilator inhaler
- No active lung infection or flare-up within 4 weeks before screening
- Stable or no background lung medications for at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
This trial studies whether long-term Staphylococcus albicans tablets can safely reduce bronchiectasis flare-ups and improve symptoms. It may help people with frequent infections/attacks due to bronchiectasis.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
This trial tests an investigational tablet for people with chronic lung diseases like bronchiectasis, COPD, or asthma who produce at least 10 mL of sputum (mucus coughed up from the lungs) each day. The goal is to see if the drug safely reduces excess airway mucus.
This study tests a new medicine for people with non-cystic fibrosis bronchiectasis. It aims to see if the drug can help reduce symptoms and improve quality of life.
Hear when a new Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.